NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said it has licensed Axis-Shield’s early-detection rheumatoid arthritis test.
Bio-Rad said the Axis-Shield assay, which is based on anti-CCP antibodies, will run on its BioPlex 2200 system.
The BP2200 is an automated multiplexing system that works at a rate of 2,200 results per hour. The platform already holds several assays designed for other autoimmune diseases.
Financial terms of the agreement were not released.